PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Negative EBIT growth while TRAW is at 100.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-25.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
610.74%
Positive net income growth while TRAW is negative. John Neff might see a big relative performance advantage.
609.26%
Positive EPS growth while TRAW is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
609.26%
Positive diluted EPS growth while TRAW is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
Positive OCF growth while TRAW is negative. John Neff would see this as a clear operational advantage vs. the competitor.
320.27%
Positive FCF growth while TRAW is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
10Y OCF/share CAGR above 1.5x TRAW's 77.68%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
419.54%
Positive OCF/share growth while TRAW is negative. John Neff might see a comparative advantage in operational cash viability.
400.10%
Positive 3Y OCF/share CAGR while TRAW is negative. John Neff might see a big short-term edge in operational efficiency.
706.07%
Net income/share CAGR above 1.5x TRAW's 98.31% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
706.07%
Positive 5Y CAGR while TRAW is negative. John Neff might view this as a strong mid-term relative advantage.
315.93%
Positive short-term CAGR while TRAW is negative. John Neff would see a clear advantage in near-term profit trajectory.
-251.89%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-251.89%
Negative 5Y equity/share growth while TRAW is at 10162.80%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-24.04%
Negative 3Y equity/share growth while TRAW is at 7609.85%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
Under 50% of TRAW's 59775.48%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-14.44%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A declining or stable vs. TRAW's 61301.60%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.